Features lightweight lotion-like texture with fast penetration
Despite these positive signals, the clinical evidence remains limited by several key factors: small sample sizes, heterogeneity in probiotic strains, dosages, and administration routes, short follow-up periods, and a primary focus on BV and VVC rather than HPV clearance as the primary endpoint
Novo has since launched a broad late-stage program for CagriSema, including the Phase III trials REDEFINE 1, which is assessing its efficacy as a weight loss therapy, and REDEFINE 2, designed to include type 2 diabetes patients with excess body weight
International travel considerations If traveling internationally, research the destination country regulations on importing injectable medications
The lyophilised peptide vial (the research compound from B.A.B.E LABS) 2